This drug has CNS depressant effects, which may include somnolence, decreased alertness, sedation, drowsiness, dizziness, and other changes in psychomotor function Label. Type Small Molecule Groups Approved StructureĮffects on the central nervous system (CNS) This drug has the propensity to completely or partially reverse the abnormal metabolism of damaged brain cells after injury 15, 9. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties 15. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance 6. It is available in both immediate acting and extended release forms Label, 18. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is aimed for use in patients with difficulties initiating sleep. Zolpidem improves sleep in patients with insomnia. Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992 Label. Ambien, Edluar, Intermezzo, Tovalt, Zolpimist Generic Name Zolpidem DrugBank Accession Number DB00425 Background
0 kommentar(er)
